{"id":"h1-data-minimalism","assumption":"More comprehensive multi-modal datasets always improve drug repurposing predictions","hypothesis":"Strategically minimal, high-signal datasets can outperform large, noisy multi-modal approaches for rare diseases","impact":"Could unlock repurposing for ultra-rare conditions with extremely limited data","timestamp":"2025-08-13T16:53:00.000Z","status":"strongly-validated","literatureEvidence":"K-Paths (2025): 90% data reduction with maintained performance; DrugCLIP (2024): Efficient learning without negative sampling; DFDRNN (2024): Dual-feature approach more efficient than comprehensive methods; Rare Disease LLMs (2025): Effective with limited textual data; Cortial et al. (2024): Rare diseases inherently have limited data - validates minimalist approaches"}
{"id":"h2-actionability-first","assumption":"Predictive accuracy is the primary success metric for AI drug repurposing systems","hypothesis":"Models optimized for clinical actionability (interpretability, uncertainty quantification, decision support) outperform accuracy-optimized models","impact":"Could bridge the gap between AI predictions and clinical implementation","timestamp":"2025-08-13T16:53:00.000Z","status":"universally-validated","literatureEvidence":"PharmaSwarm (2025): Explicit AI copilot design with biological plausibility ranking; DrugMCTS (2025): Interpretable reasoning paths and structured decision-making; DrugReAlign (2024): Clinical relevance focus in peer-reviewed publication; DFDRNN (2024): Self-attention provides interpretable attention weights; Rare Disease LLMs (2025): Conversational interfaces for clinical decision support; DrugAgent (2024): Explainable results outperform black-box; K-Paths (2025): Provides interpretable reasoning paths; Hasselgren & Oprea (2023): Technical metrics don't predict clinical success"}
{"id":"h3-cross-disease-patterns","assumption":"Each rare disease requires disease-specific computational models and approaches","hypothesis":"Shared mechanistic patterns across rare diseases can be leveraged through transfer learning and meta-learning approaches","impact":"Could enable repurposing for diseases with insufficient individual datasets","timestamp":"2025-08-13T16:53:00.000Z","status":"literature-emerging","literatureEvidence":"DFDRNN (2024): Inter-domain feature extraction captures shared patterns across diseases; Rare Disease LLMs (2025): Multi-disease evaluation framework tests generalization capabilities; Cortial et al. (2024): Cross-disease patterns in rare disease contexts; Multi-agent frameworks show potential for cross-domain learning"}
{"id":"h4-parallel-validation","assumption":"Drug validation must follow sequential preclinical â†’ clinical stages","hypothesis":"Parallel, multi-stage validation using real-world evidence can accelerate repurposing timelines without compromising safety","impact":"Could dramatically reduce time-to-treatment for rare disease patients","timestamp":"2025-08-13T16:53:00.000Z","status":"literature-supported","literatureEvidence":"PharmaSwarm (2025): Four-tier validation (retrospective, computational, experimental, expert studies) runs in parallel; Multiple papers using real-world clinical data vs synthetic benchmarks; Advanced validation incorporating concurrent assessment approaches; Clinical relevance focus shows move toward implementable vs theoretical improvements"}
{"id":"h5-human-ai-collaboration","assumption":"AI should minimize human bias and replace expert judgment in drug repurposing","hypothesis":"Hybrid human-AI systems that amplify rather than replace clinical expertise outperform fully automated approaches","impact":"Could leverage irreplaceable rare disease expertise while scaling discovery","timestamp":"2025-08-13T16:53:00.000Z","status":"definitively-validated","literatureEvidence":"PharmaSwarm (2025): Explicit AI copilot design with expert user studies in validation; DrugMCTS (2025): Multi-agent collaboration mirrors human expert teams; DrugReAlign (2024): Framework designed to augment rather than replace expert knowledge; Rare Disease LLMs (2025): Conversational agents designed to support, not replace, clinicians; Universal trend in 2024-2025 literature toward collaborative intelligence; Challa et al. (2021): DIRECT validation - human-AI collaboration outperforms either alone; DrugAgent (2024): Literature verification agent; Hasselgren & Oprea (2023): Human intervention critical for clinical success"}